An observational study in Tumors, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The VESPER study is an international, multicenter, retrospective cohort study designed to compare two surgical approaches-segmentectomy and lobectomy-for patients with non-small cell lung cancer (NSCLC) who have pathologically confirmed N1 lymph node involvement after surgery. The study is sponsor-initiated and non-funded (spontaneous study), led by the Thoracic Surgery Unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
Traditionally, lobectomy has been considered the standard surgical treatment for patients with early-stage NSCLC, based on trials showing higher local recurrence rates after more conservative resections such as segmentectomy. However, more recent randomized studies (CALGB 140503 and JCOG0802/WJOG4607L) have shown that, in selected patients with small peripheral tumors (≤2 cm) and no lymph node metastases (clinical N0), sublobar resection-particularly segmentectomy-can achieve similar long-term survival and better preservation of lung function compared with lobectomy, though with a slightly higher local recurrence risk.
Despite these findings, there is still limited scientific evidence regarding the best surgical approach for patients with occult N1 disease (i.e., lymph node metastases discovered only after surgery). Some real-world and database studies suggest that completion lobectomy might not be necessary if a radical segmentectomy with an extended lymph node dissection is performed, but these results have not been validated in a large, multicenter cohort.
The VESPER study aims to fill this evidence gap by analyzing outcomes from nine participating centers. It will include approximately 400 patients who underwent pulmonary resection (segmentectomy, multisegmentectomy, or lobectomy) for pathologic N1 NSCLC between January 2018 and December 2021. About 50 patients are expected to come from the Bologna center.
The primary objective is to compare overall survival (OS) between patients who underwent segmentectomy and those who underwent lobectomy or completion lobectomy. Secondary objectives include evaluating recurrence rates and patterns, disease-free survival (DFS), and perioperative complications (graded by the Clavien-Dindo classification).
The study population includes adults (≥18 years old) with pathologic N1 NSCLC, maximum tumor diameter ≤30 mm, and complete (R0 or R(un)) surgical resection. Patients who had emergency operations, neoadjuvant therapy, carcinoid histology, incomplete resections (R1/R2), or extended pulmonary resections (bilobectomy or pneumonectomy) are excluded.
Data will be collected retrospectively and pseudonymized using the REDCap electronic platform in accordance with Good Clinical Practice (GCP) and European data protection laws. Statistical analyses will use the Kaplan-Meier method for survival estimation, log-rank tests, and Cox proportional hazards models to adjust for potential confounders.
Because of the relatively small sample size of patients undergoing segmentectomy for pN1 disease, the study is exploratory. It is not powered for formal non-inferiority testing but aims to generate valuable real-world data to guide future prospective randomized trials.
No external or commercial funding is involved. Due to privacy restrictions, individual patient data will not be shared publicly. The expected study duration is 10 months (December 2025 - September 2026), including data analysis and dissemination.
Results will be submitted for publication in a peer-reviewed scientific journal within 12 months of study completion, regardless of the outcomes. Abstracts will also be presented at scientific conferences. Authorship will follow contribution guidelines, with the first and last authors affiliated with IRCCS AOU Bologna.
Significance:
The VESPER study will provide new evidence on the safety and long-term outcomes of segmentectomy compared with lobectomy in patients with resectable NSCLC and previously unrecognized N1 disease. By clarifying whether completion lobectomy is necessary after an initially radical segmentectomy, the study seeks to inform more personalized surgical strategies that balance oncologic effectiveness with preservation of lung function and quality of life.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 400 is above the median of 200 across 2,641 observational studies indexed under Neoplasms.
Browse Neoplasms studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 514 studies on the registry; 289 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This multicenter retrospective study will include patients who undergo surgical treatment-lobectomy, segmentectomy, or multisegmentectomy-for non-small cell lung cancer (NSCLC) with pathologically confirmed N1 lymph node involvement.
The planned data collection period is from January 2018 to December 2021. Patients will be enrolled at their first available visit by a member of the study team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall survival (OS) Recurrence rate
Time frame: baseline
distant recurrence rate
Time frame: baseline
locoregional recurrence rate
baseline
Time frame: baseline
Disease-free survival (DFS)
Time frame: baseline
Incidence of major complications (Clavien-Dindo grade 3)
Time frame: baseline
Ran from Dec 2025 to primary completion in Feb 2026, 2 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →